Physiological evaluation of residual stomach motility after local resection in conscious dogs

Kubota, Keiichi; Tatsutomi, Yusuke; Kitajima, Masaki; Mafune, Ken–ichi; Ohta, Keiichiro; Yoshida, Masashi; Suwa, Tatsushi; Kuroda, Junya; Hiki, Naoki; Seto, Yasuyuki; Kaminishi, Michio

doi:10.1007/s00595-010-4329-6

Cited by 4 publications

(5 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A previous report indicated that the bioavailability of mosapride in dogs was lower than that in other species, such as monkeys [10]. Considering the present results and previous reports [8,15], the recommended dose of mosapride in dogs is 0.75 to 2 mg/kg. Doses of up to 2 mg/kg may be required in low-response patients or cases of severe gastric motility disorders, such as gastroparesis.…”

supporting

confidence: 50%

“…Mosapride is also registered as a prokinetic agent in dogs (Pronamid; DS Pharma Animal Health Co., Ltd., Osaka, Japan) in Japan and has been used for the control of upper gastrointestinal symptoms, such as anorexia and vomiting, associated with gastrointestinal motility disorders. Previous reports demonstrated that mosapride (1 mg/kg) enhanced gastric antral motility in dogs [8,15], but the appropriate oral dose that produces prokinetic action without any adverse effects has not been determined. The main purpose of the present study was to assess the dose of mosapride as oral drug that had gastric prokinetic action in dogs.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Prokinetic Effect of the 5-HT4R Agonist Mosapride on Canine Gastric Motility

et al. 2011

View full text Add to dashboard Cite

ABSTRACT. We assessed prokinetic action of gastroprokinetic agent, mosapride in dogs. Open-label cross-over study. Six healthy beagles were administered single oral mosapride at doses of 0.5, 0.75, 1, and 2 mg/kg 30 min prior to feeding, followed by 1-week interval. The motility index (MI) of gastric contraction was ultrasonographically evaluated by change rate of antral area and contraction number. Significant increases in MI were observed at doses of 0.75 mg/kg (mean  SEM, 11.11  0.19), 1 mg/kg (11.65  0.34), and 2 mg/kg (12.04  0.34), compared with that of the control (9.37  0.51). Mosapride administration (2.0 mg/kg, BID) for 1 week had no adverse effects on blood tests or health of the animals. In conclusion, 0.75 to 2 mg/kg of mosapride produces gastric prokinetic actions without adverse effects.KEY WORDS: canine, gastrointestinal clinical symptoms, prokinetic agent.

show abstract

supporting

confidence: 50%

mentioning

confidence: 99%

Prokinetic Effect of the 5-HT4R Agonist Mosapride on Canine Gastric Motility

et al. 2011

View full text Add to dashboard Cite

show abstract

“…We believe that a potential influence on gastric motility after LECS is resection of Latarjet’s branch of the vagal nerve and gastric deformity. Kubota et al performed local gastric resection of either the lesser or the greater curvature in dogs and physiologically evaluated postoperative residual gastric motility [19]. The authors reported that resection of the lesser curvature involves resection of Latarjet’s branch of the vagal nerve, which is distributed in the lesser curvature, and decreased gastric motor activity, which probably resulted in impaired residual gastric motility.…”

Section: Discussionmentioning

confidence: 99%

Does Laparoscopic and Endoscopic Cooperative Surgery for Gastric Submucosal Tumors Preserve Residual Gastric Motility? Results of a Retrospective Single-Center Study

et al. 2014

View full text Add to dashboard Cite

BackgroundLaparoscopic and endoscopic cooperative surgery (LECS) is a minimally invasive surgical technique used to resect gastric submucosal tumors with intraluminal growth. Endoscopic submucosal dissection is used to determine the appropriate resection line from within the stomach lumen as it minimizes the stomach wall resection area and prevents postoperative stomach deformity. Although LECS is intended to preserve gastric function, few reports have evaluated postoperative residual gastric motility. Therefore, we conducted a retrospective analysis of patients who underwent LECS to determine the effects of LECS on residual gastric motility.MethodsTwenty-two patients underwent endoscopy 3 to 12 months after LECS. Patients were evaluated for endoscopic evidence of gastric motility disorder, namely food residue and occurrence/exacerbation of reflux esophagitis. We considered patients with new onset of gastric symptoms and endoscopic evidence of gastric motility disorder to have clinically relevant gastric motility disorder. We described patient characteristics, tumor location, and surgical findings.ResultsTwo of 22 patients developed clinically relevant gastric motility disorder after LECS. In one of these patients, the symptoms were not severe; only one had reduced dietary intake and had lost weight. We identified clinically relevant gastric motility disorder in two patients with gastrointestinal stromal tumors located in the lesser curvature of the stomach. The major axis of these two tumors was 34 mm and 38 mm.ConclusionsMany patients did not have clinically relevant gastric motility disorder after LECS. Further investigation is required to identify predisposing factors for gastric motility disorder.

show abstract

“…In humans, mosapride citrate has been used as a prokinetic agent for the treatment of dyspeptic symptoms of gastrointestinal disorders such as chronic gastritis, functional dyspepsia, irritable bowel syndrome, and gastric esophageal reflux disease [4]. Mosapride also enhances upper gastrointestinal motility in dogs [7, 12, 13] and has been used for the control of upper gastrointestinal symptom, such as anorexia and vomiting that are associated with gastrointestinal motility disorders. In horses, the oral administration of mosapride can increase the electrical activity of the small intestine and caecum, which suggests that mosapride promotes motility in the small intestine and caecum of horses [11].…”

mentioning

confidence: 99%

“…Ruminal motility was recorded on a polygraph (MP100A, BIOPAC Systems Inc., Santa Barbara, CA, U.S.A.) by connecting the lead wires of the transducers to the connecting cables from the amplifiers (DA100, BIOPAC Systems Inc.), was digitized by an analog-to-digital converter, and continuously recorded on a computer for analysis. To assess the amplitude of ruminal motility quantitatively, the motility index [7, 13] was determined. The motility index given by the processing system corresponded to the measurements of the area surrounded by the contraction wave and base line.…”

mentioning

confidence: 99%

Effect of mosapride on ruminal motility in cattle

Arai

Haritani

Sawada

et al. 2019

The Journal of Veterinary Medical Science

View full text Add to dashboard Cite

This study aimed to assess the effects of mosapride at various dosages on ruminal motility in cattle and the absorption kinetics of mosapride in cattle. Mosapride was rapidly absorbed after oral administration in cattle. Oral administration at dosages of 1, 3, and 10 mg/kg resulted in a dose-dependent increase in the detection time. At the 1 mg/kg dose, the motility index of rumen in cattle significantly increased at 60, 70, and 80 min (134 ± 20, 168 ± 37, 173 ± 45%, respectively), compared with that of the control. The administration of mosapride in cattle did not cause any subsequent adverse clinical signs or blood test abnormalities. It was suggested that mosapride enhanced ruminal motility without adverse effects in cattle.

show abstract

Physiological evaluation of residual stomach motility after local resection in conscious dogs

Abstract: Gastric function was maintained after gastric local resection, although its motility decreased.

Cited by 4 publications

References 24 publications

Prokinetic Effect of the 5-HT4R Agonist Mosapride on Canine Gastric Motility

Prokinetic Effect of the 5-HT4R Agonist Mosapride on Canine Gastric Motility

Does Laparoscopic and Endoscopic Cooperative Surgery for Gastric Submucosal Tumors Preserve Residual Gastric Motility? Results of a Retrospective Single-Center Study

Effect of mosapride on ruminal motility in cattle

Contact Info

Product

Resources

About